tiprankstipranks
Moderna (IT:1MRNA)
:1MRNA
Italy Market
1MRNA
Moderna
RESEARCH TOOLSreports

Moderna (1MRNA) Stock Forecast & Price Target

10 Followers
See the Price Targets and Ratings of:

1MRNA Analyst Ratings

Hold
15Ratings
Hold
2 Buy
12 Hold
1 Sell
Based on 15 analysts giving stock ratings to
Moderna
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1MRNA Stock 12 Month Forecast

Average Price Target

€70.74
▲(44.40% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is €70.74 with a high forecast of €145.57 and a low forecast of €34.25. The average price target represents a 44.40% change from the last price of €48.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","146":"€146","50.75":"€50.8","82.5":"€82.5","114.25":"€114.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145.56938159999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€145.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.74276734769231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€70.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.2516192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,50.75,82.5,114.25,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.08,56.50226012307692,63.92452024615385,71.34678036923077,78.76904049230768,86.19130061538462,93.61356073846153,101.03582086153845,108.45808098461538,115.8803411076923,123.30260123076923,130.72486135384617,138.14712147692308,{"y":145.56938159999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.08,50.746366719053256,52.41273343810651,54.079100157159765,55.745466876213015,57.41183359526627,59.078200314319524,60.74456703337278,62.41093375242603,64.07730047147929,65.74366719053255,67.41003390958579,69.07640062863905,{"y":70.74276734769231,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.08,47.939355323076924,46.79871064615384,45.65806596923077,44.51742129230769,43.376776615384614,42.23613193846154,41.09548726153846,39.954842584615385,38.814197907692304,37.67355323076923,36.532908553846156,35.39226387692308,{"y":34.2516192,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.605,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.75,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.525,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.96,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.24,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.805,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.565,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.685,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.275,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.01,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":64.02,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":49.08,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€145.57Average Price Target€70.74Lowest Price Target€34.25
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on IT:1MRNA
Michael Yee
UBS
UBS
€42.81→€128.44
Hold
162.18%
Upside
Reiterated
08/20/26
Moderna price target raised to $150 from $50 at UBSModerna price target raised to $150 from $50 at UBS
William Blair Analyst forecast on IT:1MRNA
Myles Minter
William Blair
William Blair
―
Buy
―
Upgraded
08/19/26
Moderna upgraded to Outperform from Market Perform at William BlairModerna upgraded to Outperform from Market Perform at William Blair
Citi Analyst forecast on IT:1MRNA
Geoff Meacham
Citi
Citi
€51.38
Hold
4.87%
Upside
Reiterated
08/19/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Sight Sciences (NASDAQ: SGHT)
Needham Analyst forecast on IT:1MRNA
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/19/26
Phase 3 Melanoma Success Strengthens Moderna’s Oncology Outlook, But Risk‑Reward Keeps Analyst at Hold
Jefferies Analyst forecast on IT:1MRNA
Andrew Tsai
Jefferies
Jefferies
€51.38
Hold
4.87%
Upside
Reiterated
08/19/26
Jefferies Reaffirms Their Hold Rating on Moderna (MRNA)
Morgan Stanley Analyst forecast on IT:1MRNA
Terence Flynn
Morgan Stanley
Morgan Stanley
€33.4→€76.21
Hold
55.56%
Upside
Reiterated
08/19/26
Moderna price target raised to $89 from $39 at Morgan StanleyModerna price target raised to $89 from $39 at Morgan Stanley
Bernstein Analyst forecast on IT:1MRNA
Courtney Breen
Bernstein
Bernstein
€38.53
Hold
-21.35%
Downside
Reiterated
08/19/26
Bernstein Sticks to Its Hold Rating for Moderna (MRNA)
Goldman Sachs Analyst forecast on IT:1MRNA
Salveen Richter
Goldman Sachs
Goldman Sachs
€57.37→€102.75
Hold
109.75%
Upside
Assigned
08/19/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)
J.P. Morgan Analyst forecast on IT:1MRNA
Jessica Fye
J.P. Morgan
J.P. Morgan
€34.25
Sell
-30.08%
Downside
Reiterated
08/19/26
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)
Bank of America Securities Analyst forecast on IT:1MRNA
Alec Stranahan
Bank of America Securities
Bank of America Securities
€34.25→€145.57
Hold
197.14%
Upside
Upgraded
08/19/26
Moderna upgraded to Neutral from Underperform at BofAModerna upgraded to Neutral from Underperform at BofA
RBC Capital Analyst forecast on IT:1MRNA
Luca Issi
RBC Capital
RBC Capital
€38.53→€111.32
Hold
127.23%
Upside
Reiterated
08/19/26
Moderna price target raised to $130 from $45 at RBC CapitalModerna price target raised to $130 from $45 at RBC Capital
Piper Sandler Analyst forecast on IT:1MRNA
Edward Tenthoff
Piper Sandler
Piper Sandler
€65.93
Buy
34.59%
Upside
Reiterated
08/06/26
Piper Sandler Sticks to Its Buy Rating for Moderna (MRNA)
Barclays Analyst forecast on IT:1MRNA
Eliana Merle
Barclays
Barclays
€41.1
Hold
-16.10%
Downside
Reiterated
08/05/26
Moderna (MRNA) Receives a Hold from Barclays
TD Cowen Analyst forecast on IT:1MRNA
Tyler Van Buren
TD Cowen
TD Cowen
€34.25
Hold
-30.08%
Downside
Reiterated
07/31/26
Analysts Conflicted on These Healthcare Names: BrightSpring Health Services, Inc. (NASDAQ: BTSG), Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)
Berenberg Bank Analyst forecast on IT:1MRNA
Harry Gillis
Berenberg Bank
Berenberg Bank
€38.53
Hold
-21.35%
Downside
Reiterated
07/31/26
Berenberg Bank Keeps Their Hold Rating on Moderna (MRNA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on IT:1MRNA
Michael Yee
UBS
UBS
€42.81→€128.44
Hold
162.18%
Upside
Reiterated
08/20/26
Moderna price target raised to $150 from $50 at UBSModerna price target raised to $150 from $50 at UBS
William Blair Analyst forecast on IT:1MRNA
Myles Minter
William Blair
William Blair
―
Buy
―
Upgraded
08/19/26
Moderna upgraded to Outperform from Market Perform at William BlairModerna upgraded to Outperform from Market Perform at William Blair
Citi Analyst forecast on IT:1MRNA
Geoff Meacham
Citi
Citi
€51.38
Hold
4.87%
Upside
Reiterated
08/19/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Sight Sciences (NASDAQ: SGHT)
Needham Analyst forecast on IT:1MRNA
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/19/26
Phase 3 Melanoma Success Strengthens Moderna’s Oncology Outlook, But Risk‑Reward Keeps Analyst at Hold
Jefferies Analyst forecast on IT:1MRNA
Andrew Tsai
Jefferies
Jefferies
€51.38
Hold
4.87%
Upside
Reiterated
08/19/26
Jefferies Reaffirms Their Hold Rating on Moderna (MRNA)
Morgan Stanley Analyst forecast on IT:1MRNA
Terence Flynn
Morgan Stanley
Morgan Stanley
€33.4→€76.21
Hold
55.56%
Upside
Reiterated
08/19/26
Moderna price target raised to $89 from $39 at Morgan StanleyModerna price target raised to $89 from $39 at Morgan Stanley
Bernstein Analyst forecast on IT:1MRNA
Courtney Breen
Bernstein
Bernstein
€38.53
Hold
-21.35%
Downside
Reiterated
08/19/26
Bernstein Sticks to Its Hold Rating for Moderna (MRNA)
Goldman Sachs Analyst forecast on IT:1MRNA
Salveen Richter
Goldman Sachs
Goldman Sachs
€57.37→€102.75
Hold
109.75%
Upside
Assigned
08/19/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)
J.P. Morgan Analyst forecast on IT:1MRNA
Jessica Fye
J.P. Morgan
J.P. Morgan
€34.25
Sell
-30.08%
Downside
Reiterated
08/19/26
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)
Bank of America Securities Analyst forecast on IT:1MRNA
Alec Stranahan
Bank of America Securities
Bank of America Securities
€34.25→€145.57
Hold
197.14%
Upside
Upgraded
08/19/26
Moderna upgraded to Neutral from Underperform at BofAModerna upgraded to Neutral from Underperform at BofA
RBC Capital Analyst forecast on IT:1MRNA
Luca Issi
RBC Capital
RBC Capital
€38.53→€111.32
Hold
127.23%
Upside
Reiterated
08/19/26
Moderna price target raised to $130 from $45 at RBC CapitalModerna price target raised to $130 from $45 at RBC Capital
Piper Sandler Analyst forecast on IT:1MRNA
Edward Tenthoff
Piper Sandler
Piper Sandler
€65.93
Buy
34.59%
Upside
Reiterated
08/06/26
Piper Sandler Sticks to Its Buy Rating for Moderna (MRNA)
Barclays Analyst forecast on IT:1MRNA
Eliana Merle
Barclays
Barclays
€41.1
Hold
-16.10%
Downside
Reiterated
08/05/26
Moderna (MRNA) Receives a Hold from Barclays
TD Cowen Analyst forecast on IT:1MRNA
Tyler Van Buren
TD Cowen
TD Cowen
€34.25
Hold
-30.08%
Downside
Reiterated
07/31/26
Analysts Conflicted on These Healthcare Names: BrightSpring Health Services, Inc. (NASDAQ: BTSG), Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)
Berenberg Bank Analyst forecast on IT:1MRNA
Harry Gillis
Berenberg Bank
Berenberg Bank
€38.53
Hold
-21.35%
Downside
Reiterated
07/31/26
Berenberg Bank Keeps Their Hold Rating on Moderna (MRNA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

3 Months
Mani ForooharLeerink Partners
Success Rate
29/49 ratings generated profit
59%
Average Return
-10.15%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.18% of your transactions generating a profit, with an average return of -10.15% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
32/49 ratings generated profit
65%
Average Return
-50.30%
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 65.31% of your transactions generating a profit, with an average return of -50.30% per trade.
2 Years
Mani ForooharLeerink Partners
Success Rate
33/49 ratings generated profit
67%
Average Return
-90.25%
Copying Mani Foroohar's trades and holding each position for 2 Years would result in 67.35% of your transactions generating a profit, with an average return of -90.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1MRNA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
0
0
0
0
Buy
2
3
3
3
4
Hold
39
30
42
43
42
Sell
7
8
12
11
8
Strong Sell
1
0
0
1
2
total
50
41
57
58
56
In the current month, 1MRNA has received 4 Buy Ratings, 42 Hold Ratings, and 10 Sell Ratings. 1MRNA average Analyst price target in the past 3 months is 70.74.
Each month's total comprises the sum of three months' worth of ratings.

1MRNA Financial Forecast

1MRNA Earnings Forecast

Next quarter’s earnings estimate for 1MRNA is -€1.00 with a range of -€1.38 to -€0.57. The previous quarter’s EPS was -€1.70. 1MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1MRNA is -€1.00 with a range of -€1.38 to -€0.57. The previous quarter’s EPS was -€1.70. 1MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.

1MRNA Sales Forecast

Next quarter’s sales forecast for 1MRNA is €755.34M with a range of €715.60M to €816.67M. The previous quarter’s sales results were €125.47M. 1MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.
Next quarter’s sales forecast for 1MRNA is €755.34M with a range of €715.60M to €816.67M. The previous quarter’s sales results were €125.47M. 1MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.

1MRNA Stock Forecast FAQ

What is IT:1MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is 70.74.
    What is IT:1MRNA’s upside potential, based on the analysts’ average price target?
    Moderna has 44.40% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Moderna a Buy, Sell or Hold?
          Moderna has a consensus rating of Hold, which is based on 2 buy ratings, 12 hold ratings and 1 sell ratings.
            What is Moderna’s share price target?
            The average share price target for Moderna is 70.74. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €145.57 ,and the lowest forecast is €34.25. The average share price target represents 44.40% Increase from the current price of €48.99.
              What do analysts say about Moderna?
              Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of Moderna?
                To buy shares of IT:1MRNA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.